Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas

British Journal of Cancer

Volumn 73, Issue 8, 1996, Pages 909-916

  Maelandsmo G M ^a   Florenes V A ^a   Hovig, E ^a   Oyjord T ^a   Engebraaten, O ^a   Holm, R ^a   Borresen A L ^a   Fodstad, O ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chromosome 9p21; Homozygous deletion; MTS1; Mutation; p16(INK4)

Indexed keywords

PROTEIN; RETINOBLASTOMA PROTEIN;

ARTICLE; CARCINOGENESIS; CHROMOSOME; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; MELANOMA; NEGATIVE FEEDBACK; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0029963811     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.181     Document Type: Article

References (58)

1. Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int. J. Cancer, 61, 115-120.
2. BALDIN V, LUKAS J, MARCOTE M, PAGANO M AND DRAETTA G. (1993). Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev., 7, 812-821.
3. BARTKOVA J, LUKAS J, STRAUSS M AND BARTEK J. (1995). Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene, 10, 775-778.
4. BØRRESEN AL. (1996). Constant denaturant gel electrophoresis (CDGE) in mutation screening. In Technologies for Detection of DNA Damage and Mutations. Pfeifer GP (ed). Plenum Press (in press).
5. BUCKLEY MF, SWEENEY KJ, HAMILTON JA, SINI RL, MANNING DL, NICHOLSON RI, DEFAZIO A, WATTS CK, MUSGROVE EA AND SUTHERLAND RL. (1993). Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8, 2127-2133.
6. CAIRNS P, MAO L, MERLO A, LEE DJ, SCHWAB D, EBY Y, TOKINO K, RIET PVD, BLAUGRUND JE AND SIDRANSKY D. (1994a). Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 265, 415-416.
7. CAIRNS P, TOKINO K, EBY Y AND SIDRANSKY D. (1994b). Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res., 54, 1422-1424.
8. CANNON-ALBRIGHT LA, GOLDGAR DE, MEYER LJ, LEWIS CM, ANDERSON DE, FOUNTAIN JW, HEGI ME, WISEMAN RW, PETTY EM, BALE AE, OLOPADE OI, DIAZ MO, KWIATKOWSKI D, PIEPKORN MW, ZONE JJ AND SKOLNICK MH. (1992). Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science, 258, 1148-1152.
9. CATTORETTI G, BECKER MH, KEY G, DUCHROW M, SCHLUTER C, GALLE J AND GERDES J. (1992). Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol., 168, 357-363.
10. CHURCH GM AND GILBERT W. (1984). Genomic sequencing. Proc. Natl Acad. Sci. USA, 81, 1991-1995.
11. FEINBERG AP AND VOGELSTEIN B. (1983). A technique for radio labelling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem., 132, 6-13.
12. FLØRENES VA, ØYJORD T, HOLM R, SKREDE M, BØRRESEN A-L, NESLAND JM AND FODSTAD Ø. (1994). TP53 allele loss, mutations and expression in malignant melanoma. Br. J. Cancer, 69, 253-259.
13. FORUS A, FLØRENES V, MÆLANDSMO GM, FODSTAD Ø AND MYKLEBOST O. (1994). 12q13-14 amplica in human sarcomas without MDM2 include CDK4, SAS and GADD153/CHOP. Cancer Genet. Cytogenet., 77, 200.
14. FOUNTAIN JW, KARAYIORGOU M, ERNSTOFF MS, KIRKWOOD JM, VLOCK DR, TITUS-ERNSTOFF L, BOUCHARD B, VIJAYA-SARADHI S, HOUGHTON AN, LAHTI J, KIDD VJ, HOUSMAN DE AND DRACOPOLI NC. (1992). Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. Natl.Acad. Sci. USA, 89, 10557-10561.
15. GOODRICH DW AND LEE WH. (1993). Molecular characterization of the retinoblastoma susceptibility gene. Biochim. Biophys. Acta, 1155, 43-61.
16. GRUIS NA, WEAVER-FELDHAUS J, LIU Q, FRYE C, EELES R, ORLOW I, LACOMBE L, PONCE-CASTANEDA V, LIANES P, LATRES E, SKOLNICK M, CORDON-CARDO C AND KAMB A. (1995). Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am. J. Pathol., 146, 1199-1206.
17. HE J, ALLEN JR, COLLINS VP, ALLALUNIS-TURNER MJ, GODBOUT R, DAY RSR III AND JAMES CD. (1994). CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res., 54, 5804-5807.
18. HINDS PW, DOWDY SF, EATON EN, ARNOLD A AND WEINBERG RA. (1994). Function of a human cyclic gene as an oncogene. Proc. Natl Acad. Sci. USA, 91, 709-713.
19. HOROWITZ JM, PARK SH, BOGENMANN E, CHENG JC, YANDELL DW, KAYE FJ, MINNA JD, DRYJA TP AND WEINBERG RA. (1990). Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc. Natl. Acad. Sci. USA, 87, 2775-2779.
20. HOVIG E, SMITH-SØRENSEN B, BRØGGER A AND BØRRESEN AL. (1991). Constant denaturant gel electrophoresis, a modification of denaturing gradiant gel electrophoresis, in mutation detection. Mutat. Res., 262, 63-71.
21. HSU SM, RAINE L AND FANGER H. (1981). A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am. J. Clin. Pathol., 75, 734-738.
22. HUNTER T AND PINES J. (1994). Cyclins and Cancer II: Cyclin D and CDK inhibitors come of age. Cell, 79, 573-582.
23. HUSSUSIAN CJ, STRUEWING JP, GOLDSTEIN AM, HIGGINS PA, ALLY DS, SHEAHAN MD, CLARK WH JR, TUCKER MA AND DRACOPOLI NC. (1994). Germline p16 mutations in familial melanoma. Nature Genet., 8, 15-21.
24. JIANG W, KAHN SM, TOMITA N, ZHANG YJ, LU SH AND WEINSTEIN IB. (1992). Amplification and expression of human cyclin D gene in esophageal cancer. Cancer Res., 52, 2980-2983.
25. KAMB A. (1995). Cell-cycle regulators and cancer. Trends Genet., 11, 136-140.
26. KAMB A, GRUIS NA, WEAVER-FELDHAUS J, LIU Q, HARSHMAN K, TAVTIGIAN SV, STOCKERT E, DAY RR, JOHNSON BE AND SKOLNICK MH. (1994a). A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440.
27. KAMB A, SHATTUCK-EIDENS D, EELES R, LIU Q, GRUIS NA, DING W, HUSSEY C, TRAN T, MIKI Y, WEAVER-FELDHAUS J, MCCLURE M, AITKEN JF, ANDERSON DE, BERGMAN W, FRANTS R, GOLDGAR DE, GREEN A, MACCLENNAN R, MARTIN NG, MEYER LJ, YOUL P, ZONE JJ, SKOLNICK MH AND CANNON-ALBRIGHT LA. (1994b). Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet., 8, 23-26.
28. KHATIB ZA, MATSUSHIME H, VALENTINE M, SHAPIRO DN, SHERR CJ AND LOOK AT. (1993). Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res., 53, 5535-5541.
29. KOH J, ENDERS GH, DYNLACHT BD AND HARLOW E. (1995). Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature, 375, 506-510.
30. LAMMIE GA, FANTL V, SMITH R, SCHUURING E, BROOKES S, MICHALIDES R, DICKSON C, ARNOLD A AND PETERS G. (1991). D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene, 6, 439-444.
31. LEWIS DC, WARREN N, SHUKLA VK, GRIMSHAW D, LAIDLER P AND PADUA RA. (1993). Gross rearrangements and deletions of the retinoblastoma gene are rare in malignant melanoma. Acta Derm. Venereol., 73, 236.
32. LI Y, NICHOLS MA, SHAY JW AND XIONG Y. (1994). Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res., 54, 6078-6082.
33. LIU Q, NEUHAUSEN S, MCCLURE M, FRYE C, WEAVER-FELDHAUS J, GRUIS NA, EDDINGTON K, ALLALUNIS-TURNER MJ, SKOLNICK MH, FUJIMURA FK AND KAMB A. (1995). CDNK2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene, 10, 1061-1067.
34. LUKAS J, PARRY D, AAGAARD L, MANN DJ, BARTKOVA J, STRAUSS M, PETERS G AND BARTEK J. (1995). Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature, 375, 503-506.
35. MÆLANDSMO GM, BERNER JM, FLØRENES VA, FORUS A, HOVIG E, FODSTAD Ø AND MYKLEBOST O. (1995). Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas-relationship to amplification and mRNA levels of CDK4 and CCND1. Br. J. Cancer, 72, 393-398.
36. MANIATIS T, FRITSCH EF AND SAMBROOK J. (1982). Molecular Cloning: a Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY.
37. MATSUSHIME H, ROUSSEL RA, ASHMUN RA AND SHERR CJ. (1991). Colony-stimulating factor 1 regulates novel cyclins during the GI phase of the cell cycle. Cell, 65, 701-713.
38. Ink4 requires functional retinoblastoma protein. Proc. Natl Acad. Sci. USA, 92, 6289-6293.
39. MERLO A, HERMAN JG, MAO L, LEE DJ, GABRIELSON E, BURGER PC, BAYLIN SB AND SIDRANSKY D. (1995). 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med., 1, 686-692.
40. MOTOKURA T AND ARNOLD A. (1993). Cyclin D and oncogenesis. Curr. Opin. Genet. Dev., 3, 5-10.
41. NOBORI T, MIURA K, WU DJ, LOIS A, TAKABAYASHI K AND CARSON DA. (1994). Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753-756.
42. OHTA M, NAGAI H, SHIMIZU M, RASIO D, BERD D, MASTRANGELO M, SINGH AD, SHIELDS JA, SHIELDS CL, CROCE CM AND HUEBNER K. (1994). Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res., 54, 5269-5272.
43. INK4 protein induction by 5-aza 2′ deoxycytidine. Oncogene, 11, 1211-1216.
44. POLLOCK PM, YU F, QIU L, PARSONS PG AND HAYWARD NK. (1995). Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene, 11, 663-668.
45. INK4 function. Nature Genet., 10, 114-116.
46. REED JA, LOGANZO JR F, SHEA CR, WALKER GJ, FLORES JF, GLENDENING JM, BOGDANY JK, SHIEL MJ, HALUSKA FG, FOUNTAIN JW AND ALBINO AP. (1995). Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res., 55, 2713-2718.
47. REIFENBERGER G, REIFENBERGER J, ICHIMURA K, MELTZER PS AND COLLINS VP. (1994). Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS and MDM2. Cancer Res., 54, 4299-4303.
48. SERRANO M, HANNON GJ AND BEACH D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/ CDK4. Nature, 366, 704-707.
49. INK4. Science, 267, 249-252.
50. SPRUCK III CH, GONZALEZ-ZULUETA M, SHIBATA A, SIMONEAU AR, LIN M-F, GONZALES F, TSAI YC AND JONES PA. (1994). p16 gene in uncultured tumours. Nature, 370, 183-184.
51. SUN Y, HILDESHEIM A, LANIER AE, CAO Y, YAO KT, RAAB-TRAUB N AND YANG CS. (1995). No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas. Oncogene, 10, 785-788.
52. INK4. Cancer Res., 54, 5816-5820.
53. TAM SW, THEODORAS AM, SHAY JW, DRAETTA GF AND PAGANO M. (1994b). Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in Gl progression. Oncogene, 9, 2663-2674.
54. WADAYAMA B, TOGUCHIDA J, SHIMIZU T, ISHIZAKI K, SASAKI MS, KOTOURA Y AND YAMAMURO T. (1994). Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res., 54, 3042-3048.
55. WEINBERG RA. (1995). The retinoblastoma protein and cell cycle control. Cell, 81, 323-330.
56. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science, 269, 1281-1284.
57. XU HJ, HU SX, CAGLE PT, MOORE GE AND BENEDICT WF. (1991). Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res., 51, 2735-2739.
58. YEAGER T, STADLER W, BELAIR C, PUTHENVEETTIL J, OLOPADE O AND REZNIKOFF C. (1995). Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res., 55, 493-497.